Want to see LUNG full AI Analyst Report?
LUNG Stock Chart & Stats
$1.80
-$0.17(-2.57%)
At close: 4:00 PM EST
$1.80
-$0.17(-2.57%)
Day’s Range― - ―
52-Week Range$1.13 - $3.88
Previous CloseN/A
Volume95.69K
Average Volume (3M)449.29K
Market Cap
$59.13M
Enterprise Value$48.51
Total Cash (Recent Filing)$61.57M
Total Debt (Recent Filing)$56.29M
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Jul 29, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding42,237,200
10 Day Avg. Volume193,433
30 Day Avg. Volume449,291
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$3.50Price Target Upside94.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.14
Revenue Forecast (FY)$90.87M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained mid-70% gross margins are a durable structural strength for a single‑use device business. High gross profit per procedure gives Pulmonx room to fund R&D, support sales investment and absorb pricing/reimbursement pressure while requiring fewer incremental units to cover costs.
Lower Operating Expense TrajectoryA >10% cut in ongoing operating expenses and improved adjusted EBITDA trends indicate meaningful structural cost discipline. Lower fixed cost base reduces the cash burn needed to reach breakeven and improves the probability that revenue recovery will translate into sustainable profitability.
Extended Liquidity RunwayMaterial cash on hand plus a five‑year $60M facility extends runway and reduces near‑term refinancing pressure. The facility (and access to an incremental $20M on milestones) gives management time to execute the commercial ramp and clinical programs without immediate funding stress.
Bears Say
Revenue Decline And Demand RiskA multi‑period revenue decline undermines operating leverage in a high‑gross‑margin model: slower procedure volumes and disrupted international sales limit scaling benefits and prolong the timeline to profitability, raising execution risk for the recovery plan.
Negative Cash Flow And Financing RelianceConsistent negative operating and free cash flow means the business relies on external financing to sustain growth and cover losses. This constrains strategic flexibility, increases dilution or leverage risk over time, and makes execution of commercialization plans contingent on continued funding access.
Elevated Leverage And Balance‑sheet PressureDebt exceeding equity and a shrinking equity base reduce financial resilience. Secured financing with warrants and performance conditions raises covenant and dilution risk, limiting the company's ability to absorb slower growth or invest opportunistically if recovery takes longer than planned.
Pulmonx News
LUNG FAQ
What was Pulmonx Corporation’s price range in the past 12 months?
Pulmonx Corporation lowest stock price was $1.13 and its highest was $3.88 in the past 12 months.
What is Pulmonx Corporation’s market cap?
Pulmonx Corporation’s market cap is $59.13M.
When is Pulmonx Corporation’s upcoming earnings report date?
Pulmonx Corporation’s upcoming earnings report date is Jul 29, 2026 which is in 8 days.
How were Pulmonx Corporation’s earnings last quarter?
Pulmonx Corporation released its earnings results on Apr 29, 2026. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.327 by -$0.003.
Is Pulmonx Corporation overvalued?
According to Wall Street analysts Pulmonx Corporation’s price is currently Undervalued.
Does Pulmonx Corporation pay dividends?
Pulmonx Corporation does not currently pay dividends.
What is Pulmonx Corporation’s EPS estimate?
Pulmonx Corporation’s EPS estimate is -0.28.
How many shares outstanding does Pulmonx Corporation have?
Pulmonx Corporation has 42,237,200 shares outstanding.
What happened to Pulmonx Corporation’s price movement after its last earnings report?
Pulmonx Corporation reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.327. Following the earnings report the stock price went up 6.667%.
Which hedge fund is a major shareholder of Pulmonx Corporation?
Currently, no hedge funds are holding shares in LUNG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.50 (94.44% Upside)
$3.50 (94.44% Upside)
Blogger Sentiment
Bearish
LUNG Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 2.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $144.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-20.41%
Trailing 12-Months
Company Description
Pulmonx Corporation
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
LUNG Stock 12 Month Forecast
Average Price Target
$3.50
▲(94.44% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―
Ownership Overview
14.06% Insiders
16.95% Mutual Funds
0.24% Other Institutional Investors
64.67% Public Companies and
Individual Investors